Taken together, these results suggest that H19 effectively inhibits primary prolactinoma progression by inhibiting 4E-BP1 phosphorylation and that increasing H19 expression may serve as a potential therapeutic strategy for pituitary tumours. The gene discussed is H19; the disease is pituitary tumor.